| LBCTR2020011380 | CINC424A2X01B | Rollover An Open Label, Multi-center, Phase IV Rollover Protocol for Patients Who Have Completed a Global Novartis or Incyte Sponsored Ruxolitinib (INC424) or Ruxolitinib and Panobinostat (LBH589) Combination Study and Are Judged by the Investigator to Benefit From Continued Treatment | An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to benefit from continued treatment | Interventional | Complete | 02/01/2020 |
| LBCTR2019121368 | CINC280A2201 | Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer | A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) | Interventional | Complete | 25/12/2019 |
| LBCTR2019020189 | CICL670FIC05 | Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation | Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation | Interventional | Complete | 06/02/2019 |
| LBCTR2019030206 | CICL670F2429 | Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) | A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets | Interventional | Complete | 28/02/2019 |
| LBCTR2020011375 | CICL670E2419 | THETIS- Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia | An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia | Interventional | Complete | 01/01/2020 |
| LBCTR2024015424 | CHS1221 | A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum | A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum | Interventional | Recruiting | 04/09/2023 |
| LBCTR2021024744 | CEUA 056 | The Effect of Rhythmic Auditory Stimulation on Gait in Chronic Stroke Patients | The Effect of Rhythmic Auditory Stimulation Tempo Shifts Application on Gait Parameters in Chronic Stroke Patients: A Pilot Study | Interventional | Recruiting | 14/02/2021 |
| LBCTR2022095130 | CEHDF2040 | Ergonomics and Mindfulness for preventing musculoskeletal pain and a better quality of life | Effect of ergonomics and mindfulness on musculoskeletal pain and quality of life for office workers: a randomized controlled trial | Interventional | Recruiting | 19/09/2022 |
| LBCTR2021054816 | CEHDF 1787 | Effects of different mental training techniques on fine motor performance. | Comparison between the effects of Neurofeedback training and Motor imagery training on motor performance in a finger tapping task. | Interventional | Recruiting | 16/06/2021 |
| LBCTR2021044784 | CBYL719H12301 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation | Interventional | Suspended | 15/04/2021 |